In early August, Novo Nordisk announced that Wegovy reduces the risk of heart attack, stroke or heart-related death in people with cardiovascular disease and obesity by 20%, a result expected to boost use of the medicine even further
Staying in touch ensures your treatment stays on track and works for your body
Jeff is the founder of Zimon LLC, a boutique ERISA and employee benefits law firm, and is also the Creator and Founder of an industry leading group benefits compliance resource, EZ ERISAPlan - www.ezerisaplan.com .
For tendons with their naturally limited blood supply, this represents a potentially transformative effect that addresses the core healing bottleneck
This is particularly helpful for needle-anxious beginners who need to build confidence
Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study